Journal
MOVEMENT DISORDERS
Volume 36, Issue 11, Pages 2508-2518Publisher
WILEY
DOI: 10.1002/mds.28639
Keywords
biomarker; plasma; extracellular vesicles; α ‐ synuclein; Parkinson' s disease
Categories
Funding
- Michael J. Fox Foundation for Parkinson's Research
- German Research Foundation [SCHN1265/1-1]
Ask authors/readers for more resources
This study aimed to examine the diagnostic value of alpha-synuclein in plasma extracellular vesicles from patients with Parkinson's disease (PD). Results showed that alpha-synuclein concentration in plasma extracellular vesicles could provide good discrimination between different neurodegenerative diseases, suggesting its potential as a diagnostic biomarker for PD. The study highlights the importance of extracellular vesicle-derived alpha-synuclein in disease pathology and diagnosis.
Background Extracellular vesicles are small vesicles that are released from many cells, including neurons. alpha-Synuclein has recently been described in extracellular vesicles derived from the central nervous system and may contribute to the spreading of disease pathology in alpha-synuclein-related neurodegeneration. Objectives We aimed to examine the potential diagnostic value of alpha-synuclein in plasma extracellular vesicles from patients with Parkinson's disease (PD). Methods Preanalytical variables were studied to establish an optimized assay for preparation of plasma extracellular vesicles and detection of extracellular vesicle-derived alpha-synuclein. Plasma samples were obtained from 2 independent cohorts. The Tubingen cohort contained 96 patients with PD, 50 patients with dementia with Lewy bodies, 50 patients with progressive supranuclear palsy (PSP), and 42 healthy controls; the Kassel cohort included 47 patients with PD, 43 patients with dementia with Lewy bodies, and 36 controls with secondary parkinsonian syndromes. Extracellular vesicles were prepared from total plasma by size exclusion chromatography and quantified by nanoparticle tracking analysis, alpha-synuclein content was measured by an electrochemiluminescence assay. Results alpha-Synuclein concentration in plasma extracellular vesicles provided the best discrimination between PD, dementia with Lewy bodies, PSP, and healthy controls, with an area under the curve of 0.804 (PD vs dementia with Lewy bodies), 0.815 (PD vs. PSP), and 0.769 (PD vs healthy controls) in the Tubingen cohort. Results were validated in the Kassel cohort. Conclusions The concentration of alpha-synuclein in plasma extracellular vesicles may serve as a potential diagnostic biomarker for PD. (c) 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available